GlassScriptPhysician profile
Peter Faulk
NPI 1649965484
$2,482.94
in general payments reported to CMS, 2019-2025
13 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677 · Travel and Lodging: $685 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.97 |
| Travel and Lodging | $684.98 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,046.40 | 2025 | Interstim |
| Abbvie INC. | $372.03 | 2025 | |
| Janssen Biotech, INC. | $174.07 | 2025 | Tremfya |
| Gilead Sciences, INC. | $149.71 | 2025 | Livdelzi |
| Madrigal Pharmaceuticals | $138.86 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $116.50 | 2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $114.75 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $99.77 | 2025 | |
| Ardelyx, INC. | $82.21 | 2025 | Ibsrela |
| Pfizer INC. | $64.94 | 2025 | |
| Aimmune Therapeutics, INC. | $57.96 | 2025 | Zenpep |
| Genzyme Corporation | $46.03 | 2025 | |
| Novo Nordisk INC | $19.71 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Faulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.